FDA Recommends Scheduling 7-Hydroxymitragynine, Distinguishing Concentrated Products From Kratom Leaf
The FDA recommended that the DEA schedule concentrated 7-hydroxymitragynine products under the Controlled Substances Act while explicitly distinguishing them from natural kratom leaf, issued warning letters to seven companies, and sent alerts to physicians and consumers. Kansas Governor Laura Kelly signed a bill placing 7-OH substances in Schedule I, and the CDC reported that kratom-related poison center calls rose approximately 1,200 percent over the past decade.
The FDA recommended that the DEA place concentrated 7-hydroxymitragynine (7-OH) products on the federal controlled substances schedule while drawing an explicit line between those products and natural kratom leaf. Commissioner Marty Makary described 7-OH tablets, gummies, and shots as a distinct category from kratom, and the agency issued warning letters to seven companies, sent alerts to physicians, and published a new report on 7-OH health risks. Separately, Kansas signed 7-OH substances into Schedule I, and a CDC analysis reported a roughly 1,200 percent rise in kratom-related poison center calls over the past decade.
FDA Recommends DEA Schedule Concentrated 7-OH
The FDA announced that it is sending a letter to the DEA recommending that concentrated 7-hydroxymitragynine products be placed under the Controlled Substances Act. The agency said it also issued warning letters in June to seven companies distributing 7-OH products, including tablets, gummies, drink mixes, and shots. The FDA sent a "Dear Doctor" letter to health care professionals and published a consumer warning about 7-OH.
Commissioner Makary said the agency is pursuing a "concentration threshold" approach to distinguish concentrated 7-OH products from the trace amounts of 7-hydroxymitragynine that occur naturally in kratom leaf, according to a press briefing. He also said the FDA has "no evidence" that kratom is safe or effective for any medical use, a position consistent with the agency's standing kratom page.
The scheduling recommendation now goes to the DEA, which holds final scheduling authority through its own rulemaking and public comment process. The DEA has not announced any new kratom-specific action. Its most recent publicly stated position is a fact sheet describing kratom's alkaloids and their effects, last updated after the agency's 2016 scheduling attempt was withdrawn following public backlash.
The American Kratom Association (AKA) applauded the recommendation, calling it a "science-driven" move. The AKA specifically praised HHS Secretary Robert F. Kennedy Jr. and Commissioner Makary for targeting concentrated 7-OH while preserving access to natural kratom leaf products. The position aligns with the AKA's recent policy advisory to state attorneys general urging enforcement against 7-OH products sold as kratom.
The Global Kratom Coalition (GKC) has separately endorsed a federal bill introduced by Rep. Gus Bilirakis that would classify synthetic 7-OH as a Schedule I substance. GKC has argued that synthetically derived 7-hydroxymitragynine should not be treated as a leaf kratom product.
Kansas Signs 7-OH Into Schedule I
Kansas Governor Laura Kelly signed House Bill 2365, placing 7-OH-related substances in Schedule I, according to the governor's office. Kelly said the state should "safeguard the health of Kansans" until scientific reviews demonstrate positive benefits and minimal risks.
The signing follows an earlier round of state-level scheduling actions and adds Kansas to a growing list of states that have moved to restrict 7-OH independently of federal action. A Rockefeller Institute of Government analysis found that states are moving in three directions: outright bans, controlled substance scheduling, and regulated sales frameworks with consumer protection requirements.
Arizona AG Warns on 7-OH; Idaho Advances Consumer Protection
Arizona Attorney General Kris Mayes issued a consumer alert warning that products sold as kratom or "all-natural" supplements may contain concentrated synthetic substances, including 7-hydroxymitragynine. Mayes said she plans to work with lawmakers to strengthen Arizona's kratom laws and urged consumers to avoid mislabeled or "extra strength" products lacking clear ingredient and alkaloid disclosures.
In Idaho, Senate Bill 1418 would create a Kratom Consumer Protection and Safety Act that prohibits adulterated kratom products, sets a 21-and-older age limit, allows random and unannounced inspections, and adds misdemeanor penalties for knowingly misrepresenting age. The bill is advancing through the legislature.
CDC Reports 1,200 Percent Rise in Kratom Poison Center Calls
A CDC analysis published in the Morbidity and Mortality Weekly Report found that kratom-related reports to U.S. poison centers rose approximately 1,200 percent from 2015 to 2025, with 2025 setting a record. The report found that severe outcomes were especially associated with multiple-substance exposures, and that about half of cases involving multiple substances required hospitalization.
The CDC data does not distinguish between exposures involving natural kratom leaf and those involving concentrated 7-OH products, a distinction that the FDA's new concentration-threshold approach is designed to address. The AKA and GKC have both argued that the spike in adverse reports is driven primarily by concentrated 7-OH products rather than by traditional kratom leaf.
Sources
-
FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers
U.S. Food and Drug Administration
FDA announced it is recommending DEA schedule concentrated 7-hydroxymitragynine products, issued warning letters to seven companies, and sent advisories to physicians and consumers.
-
Kratom-Related Exposures Reported to U.S. Poison Centers, 2015-2025
CDC Morbidity and Mortality Weekly Report
CDC analysis found kratom-related poison center reports rose approximately 1,200 percent from 2015 to 2025, with severe outcomes especially associated with multiple-substance exposures.
-
Governor Kelly Signs House Bill 2365
Office of the Governor of Kansas
Kansas Governor Laura Kelly signed HB 2365 placing 7-hydroxymitragynine-related substances in Schedule I, saying the state should safeguard the health of Kansans.
-
AG Mayes Consumer Alert: Kratom
Arizona Attorney General
Arizona Attorney General Kris Mayes warned that products sold as kratom may contain concentrated synthetic substances including 7-hydroxymitragynine and said she would work with lawmakers to strengthen Arizona's kratom laws.
-
Senate Bill 1418: Idaho Kratom Consumer Protection and Safety Act
Idaho Freedom Foundation
Idaho SB 1418 would create a Kratom Consumer Protection and Safety Act, prohibit adulterated products, set a 21-and-older age limit, and allow random inspections.
-
AKA Response to FDA 7-OH Scheduling Recommendation
American Kratom Association
AKA applauded Secretary Kennedy and Commissioner Makary for recommending Schedule I classification of 7-OH, calling the move science-driven.
-
FDA Targets Kratom Compound for Regulation
Partnership to End Addiction
FDA initiated a process recommending DEA place 7-OH into Schedule I while saying the action is not focused on natural kratom leaf products.
-
The Evolving Kratom Policy Landscape
Rockefeller Institute of Government
Policy overview noting states have moved in three directions on kratom: ban, schedule, or regulate, with bills pending in multiple states.
-
FDA and Kratom
U.S. Food and Drug Administration
FDA maintains kratom is not lawfully marketed as a dietary supplement or food additive and warns consumers about associated risks.